WOMEN’S ANSWERS / ANIMAL BEHAVIOR
What did researchers learn about PT-141?
Bremelanotide is a drug studied for a distressing loss of desire. Here you can compare the large Phase 3 trials done before approval with smaller tests and animal findings.
What’s the clearest finding from the trials?
PT-141 research asks whether changing brain activity can increase sexual interest. The strongest evidence comes from women distressed by having little desire.
In the two large trials, women’s desire increased modestly and their upset over low interest eased [3][4]. Feeling sick was the chief drawback during treatment and longer follow-up.
In a scan study, women described increased sexual interest alongside a different brain response while viewing sexual pictures [5]. You can also read a review questioning whether the trial gains mattered enough [14].
Rats and animals related to monkeys developed erections, and tests detected greater brain cell activity [1]. Female rats sought males more often, without becoming more active overall [2].
In 2025, treatment didn’t increase hamsters’ preference for a location where earlier sex had occurred [6]. Researchers tested whether the drug made that remembered sexual experience more rewarding.
Did the drug make animals seek mates or find sex more rewarding?
Early PT-141 tests found erections in rats and animals related to monkeys. Tests found that the cells helping govern desire were more active.
Larger amounts strengthened erections in animals. Men who had struggled to get erections also responded quickly during early research [1].
Female rats tried harder to attract males after PT-141. Back arching during mounting, time between mating attempts, and ordinary movement didn’t change [2].
No earlier drug had been reported to increase that mate-seeking behavior. Rat findings can’t prove benefit for women.
The 2025 hamster test measured preference for a location linked with remembered sex. Treatment didn’t strengthen that preference, giving no evidence that sex became more rewarding [6].
Scientists also measured chemical messages inside brain cells. These messages tell cells to make the parts where the drug attaches.
The amount of those messages didn’t change after treatment. That result concerns this cell response, without ruling out every other drug effect.
PT-141 for women: what did Phase 3 trials find?
RECONNECT enrolled 1,267 women whose loss of interest in sex caused distress before their periods ended. The two Phase 3 trials tested treatment the same way.
Medicine shots contained 1.75 milligrams, each a thousandth of a gram. Placebo shots looked the same but lacked the drug.
After 24 weeks, women receiving medicine described increased desire and reduced distress compared with women receiving placebo [3]. Question 13 asked women to rate distress about low desire [3].
Both trials found improvement in the two complaints being tested. You can recognize those gains without assuming a large everyday benefit.
Then 684 women joined a 52-week follow-up, all knowingly receiving medicine [4]. Desire gains lasted, with similar side effects and nausea the leading complaint.
A separate study scanned 31 women troubled by their lack of sexual interest. Those women described greater interest, alongside changed brain activity during viewing of sexual pictures [5].
PT-141 for men: what keeps the evidence uncertain?
Early testing found quick erections among men who had difficulty getting an erection. Stronger responses followed larger drug amounts [1].
Nose-spray tests found erections above about 7 milligrams, each a thousandth of a gram [13]. Blood tests found that the body took in different amounts of drug between uses, so researchers abandoned sprays.
Reviews place the desire effect of bremelanotide within the brain [10][13]. Familiar erection pills ease blood flow through relaxation of muscles in vessel walls.
Testing in men didn’t bring approval to treat their erection problems. You still lack a settled answer about benefit and safety for men.
Safarinejad and Hosseini published a study of lasting erection trouble in 2008. The journal issued a warning in 2023 about the reliability of those findings.
The information available here doesn’t explain what prompted that warning. You can’t treat the disputed study as dependable proof of benefit.
Were women helped enough to notice a useful difference?
The large trials found increased desire, but the gain was modest. You can ask whether that changed a woman’s daily life enough.
A review found the Phase 3 differences unlikely to result from chance. The author still questioned whether women’s modest desire increase and reduced distress meant enough in everyday life [14].
A 2024 review returned to that doubt about useful improvement [14]. A better answer on a study form doesn’t necessarily mean a large benefit.
Researchers study related brain actions for excess weight and illness-related weight loss. A review cited the 2019 approval as evidence that bremelanotide had passed safety review for its approved use [8].
That review can’t establish safety for other drugs or weight treatment. Reviews also discuss the brain’s part in women’s sexual desire [11].
Approval excludes men’s treatment, sexual performance, and weight treatment. The women’s results don’t prove benefits for those purposes.